Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Robert Wild, Ph.D., has been appointed as Chief Scientific Officer and Senior Vice President, Research.
“Robert has broad, valuable experience in oncology drug discovery and development in both pharma and biotech settings, spanning small molecules and biologics,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “His deep understanding of oncology, coupled with his extensive experience in translational medicine and the integration of biomarker strategies in discovery and development programs, will help drive Ignyta’s success as we strive to provide new oncology treatment options for patients.”
Help employers find you! Check out all the jobs and post your resume.
